Customization: | Available |
---|---|
CAS No.: | 439081-18-2 |
Formula: | C24h25clfn5o3 |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
CAS Number | 439081-18-2 |
Product Name | Afatinib |
Molecular formula | C24H25ClFN5O3 |
Chemical Name | BIBW 2992 |
Molecular weight | 485.94 |
Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim.
It acts as a angiokinase inhibitor.
Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal receptor 2 (Her2) and epidermal receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation TKIs likeerlotinib , but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.